Indivior (NASDAQ:INDV) Raised to “Strong-Buy” at Barclays

Indivior (NASDAQ:INDV) was upgraded by equities research analysts at Barclays to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

A number of other research firms have also issued reports on INDV. Weiss Ratings lowered Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Indivior has a consensus rating of “Buy” and an average target price of $40.29.

Indivior Stock Performance

NASDAQ INDV opened at $38.28 on Thursday. The firm has a market cap of $4.67 billion, a PE ratio of 19.63 and a beta of 0.88. Indivior has a one year low of $13.45 and a one year high of $41.00. The firm’s fifty day moving average is $36.06 and its two-hundred day moving average is $34.44.

Indivior (NASDAQ:INDV) last announced its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. The business had revenue of $317.00 million during the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. Research analysts predict that Indivior will post 4.05 earnings per share for the current year.

Insider Transactions at Indivior

In other news, CFO Ryan Preblick sold 36,000 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the transaction, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. This represents a 11.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Institutional Trading of Indivior

Institutional investors have recently modified their holdings of the business. Quarry LP acquired a new position in Indivior during the third quarter worth $26,000. Raymond James Financial Inc. acquired a new stake in Indivior in the second quarter valued at $26,000. Salomon & Ludwin LLC purchased a new stake in shares of Indivior during the 4th quarter worth $30,000. Harbor Capital Advisors Inc. boosted its position in shares of Indivior by 309.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Indivior by 72.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after purchasing an additional 460 shares during the period. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.